GlassScriptPhysician profile
Lee H Novick
NPI 1366500456
$10,535.49
in general payments reported to CMS, 2019-2025
25 companies · $2,468 in 2025
The $2,468 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $741 · 2021: $2,786 · 2022: $1,092 · 2023: $859 · 2024: $1,657 · 2025: $2,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,983.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,374.31 | 2019-2025 | Clareon, Rocklatan, Argos |
| Carl Zeiss Meditec, INC. | $1,855.00 | 2021 | |
| Glaukos Corporation | $888.25 | 2022-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Idosetr, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $811.14 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Catalys System |
| Rxsight INC | $660.59 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $464.49 | 2023-2025 | Miebo, Envista Envy Iol, Envista Envy |
| Harrow Eye, LLC | $385.64 | 2025 | Iheezo, Vevye, Triesence |
| Abbvie INC. | $320.51 | 2022-2025 | |
| Lensar, INC. | $272.35 | 2024 | Lensar Laser System |
| Sun Pharmaceutical Industries INC. | $271.50 | 2019-2025 | |
| Allergan, INC. | $242.93 | 2019-2022 | |
| Amgen INC. | $181.08 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $149.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $97.02 | 2019 | |
| Aerie Pharmaceuticals, INC. | $86.42 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $72.22 | 2025 | Xdemvy |
| Thea Pharma INC. | $63.48 | 2022-2025 | Iyuzeh |
| Sight Sciences, INC. | $59.91 | 2020-2025 | Sion Surgical Instrument, Omni Surgical System |
| Oyster Point Pharma, INC. | $58.89 | 2022-2025 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $48.09 | 2025 | Omidria |
| Ocular Therapeutix, INC. | $47.75 | 2023-2025 | Dextenza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Akorn, INC. | $38.27 | 2019-2020 | |
| Alcon Research LLC | $25.27 | 2019 | |
| Oasis Medical, INC. | $21.83 | 2025 | Oasis Tears |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Novick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.